Cargando…

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial

BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Mösges, R., Bachert, C., Panzner, P., Calderon, M. A., Haazen, L., Pirotton, S., Wathelet, N., Durham, S. R., Bonny, M.‐A., Legon, T., von Frenckell, R., Pfaar, O., Shamji, M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175232/
https://www.ncbi.nlm.nih.gov/pubmed/29512827
http://dx.doi.org/10.1111/all.13433
_version_ 1783361461173616640
author Mösges, R.
Bachert, C.
Panzner, P.
Calderon, M. A.
Haazen, L.
Pirotton, S.
Wathelet, N.
Durham, S. R.
Bonny, M.‐A.
Legon, T.
von Frenckell, R.
Pfaar, O.
Shamji, M. H.
author_facet Mösges, R.
Bachert, C.
Panzner, P.
Calderon, M. A.
Haazen, L.
Pirotton, S.
Wathelet, N.
Durham, S. R.
Bonny, M.‐A.
Legon, T.
von Frenckell, R.
Pfaar, O.
Shamji, M. H.
author_sort Mösges, R.
collection PubMed
description BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double‐blind, placebo‐controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. RESULTS: The mean reduction in CSMS in the LPP vs placebo group was −15.5% (P = .041) during the peak period and −17.9% (P = .029) over the entire pollen season. LPP‐treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ≤30 minutes in 10.5% of LPP‐treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication. CONCLUSION: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well‐tolerated.
format Online
Article
Text
id pubmed-6175232
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61752322018-10-15 Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial Mösges, R. Bachert, C. Panzner, P. Calderon, M. A. Haazen, L. Pirotton, S. Wathelet, N. Durham, S. R. Bonny, M.‐A. Legon, T. von Frenckell, R. Pfaar, O. Shamji, M. H. Allergy ORIGINAL ARTICLES BACKGROUND: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. METHODS: In a randomized, double‐blind, placebo‐controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. RESULTS: The mean reduction in CSMS in the LPP vs placebo group was −15.5% (P = .041) during the peak period and −17.9% (P = .029) over the entire pollen season. LPP‐treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ≤30 minutes in 10.5% of LPP‐treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication. CONCLUSION: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well‐tolerated. John Wiley and Sons Inc. 2018-06-21 2018-09 /pmc/articles/PMC6175232/ /pubmed/29512827 http://dx.doi.org/10.1111/all.13433 Text en © 2018 The Authors. Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Mösges, R.
Bachert, C.
Panzner, P.
Calderon, M. A.
Haazen, L.
Pirotton, S.
Wathelet, N.
Durham, S. R.
Bonny, M.‐A.
Legon, T.
von Frenckell, R.
Pfaar, O.
Shamji, M. H.
Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
title Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
title_full Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
title_fullStr Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
title_full_unstemmed Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
title_short Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
title_sort short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: a randomized, multicenter, double‐blind, placebo‐controlled trial
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175232/
https://www.ncbi.nlm.nih.gov/pubmed/29512827
http://dx.doi.org/10.1111/all.13433
work_keys_str_mv AT mosgesr shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT bachertc shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT panznerp shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT calderonma shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT haazenl shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT pirottons shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT watheletn shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT durhamsr shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT bonnyma shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT legont shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT vonfrenckellr shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT pfaaro shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial
AT shamjimh shortcourseofgrassallergenpeptidesimmunotherapyover3weeksreducesseasonalsymptomsinallergicrhinoconjunctivitiswithwithoutasthmaarandomizedmulticenterdoubleblindplacebocontrolledtrial